Create A 5- To 6-Slide PowerPoint Presentation For Staff D ✓ Solved

Create a 5- to 6-slide PowerPoint presentation for a staff d

Create a 5- to 6-slide PowerPoint presentation for a staff development meeting that presents different approaches for implementing the stepwise approach to asthma treatment. Describe long-term control and quick-relief treatment options for asthma patients (including adults and children) and the impact these drugs may have. Explain the stepwise approach to asthma treatment and management and how stepwise management assists health care providers and patients in gaining and maintaining control of the disease. Be specific and include examples of applying the stepwise approach to a patient in your practice.

Paper For Above Instructions

Executive summary

This paper outlines content suitable for a 5–6 slide staff development presentation on implementing the stepwise approach to asthma management. It covers: long-term control and quick-relief medication classes, drug impacts in adults and children, a clear explanation of the stepwise strategy, practical application to a patient case, and how stepwise management helps clinicians and patients achieve and sustain asthma control (GINA, 2024; NHLBI, 2020).

Slide 1 — Objectives and clinical context

Objective: Equip staff with actionable approaches to implement the stepwise asthma care model in clinic workflows. Context: Asthma is a variable chronic airway disease requiring personalized therapy that balances symptom control and medication risk. The stepwise model tailors intensity of therapy to current control and future risk (GINA, 2024).

Slide 2 — Long-term control medications (maintenance)

Key long-term controllers and their clinical impacts:

  • Inhaled corticosteroids (ICS): cornerstone for persistent asthma; reduce airway inflammation, exacerbations, and need for systemic steroids. Dose-dependent side effects include local candidiasis, dysphonia, and rare systemic effects at high doses (Barnes, 2011; GINA, 2024).
  • Long-acting beta2-agonists (LABA) used in combination with ICS: improve symptom control and lung function; never used as monotherapy (GINA, 2024).
  • Leukotriene receptor antagonists (LTRAs): oral option helpful in allergic or aspirin-sensitive phenotypes and in children who cannot use inhalers reliably; modest efficacy versus ICS (NICE, 2017).
  • Biologic agents (anti-IgE, anti-IL5/5R, anti-IL4R): indicated for severe eosinophilic/allergic phenotypes; reduce exacerbations and oral steroid dependence but require specialist referral (GINA, 2024; BTS/SIGN, 2019).
  • Theophylline and others: limited use due to narrow therapeutic index and side effects; generally not first-line (NHLBI, 2020).

Impact on adults vs children: ICS dosing and growth monitoring are considerations in children; LTRAs are often better tolerated for pediatric use; inhaler technique and device choice are critical in both groups (CDC, 2023; AAAAI, 2021).

Slide 3 — Quick-relief (rescue) treatments

Primary quick-relief options:

  • Short-acting beta2-agonists (SABA; e.g., albuterol/salbutamol): fast bronchodilation for acute symptoms; over-reliance signals poor control and increased exacerbation risk (Reddel et al., 2019).
  • Low-dose ICS-formoterol as-needed: recent guideline changes endorse ICS-formoterol as both maintenance and reliever in many patient groups to reduce exacerbations and steroid exposure (GINA, 2024).
  • Systemic corticosteroids: short courses for moderate-severe exacerbations; minimize cumulative exposure due to systemic adverse effects (NHLBI, 2020).

Clinical impact: Educate patients to avoid frequent SABA-only reliance and to recognize when escalation and medical review are required (CDC, 2023).

Slide 4 — Explain the stepwise approach

Core principles:

  • Assess control and risk: use symptom frequency, rescue use, activity limitation, lung function, and exacerbation history (GINA, 2024).
  • Step up when control is inadequate or during periods of increased risk; step down when control is sustained to find the minimal effective therapy (NICE, 2017).
  • Personalize treatment: match drug choice to phenotype (e.g., allergic, eosinophilic) and age, account for comorbidities and inhaler technique (BTS/SIGN, 2019).

Operationalizing steps: Provide a concise algorithm slide showing Step 1 (intermittent — as-needed reliever or ICS-formoterol PRN), Step 2 (low-dose ICS maintenance), Step 3 (low-dose ICS/LABA), Step 4 (medium/high-dose ICS/LABA), Step 5 (add-on biologic or oral steroid management and specialist referral) (GINA, 2024).

Slide 5 — Practical case example from practice

Case: A 10-year-old child with intermittent wheeze escalating to weekly symptoms and two SABA uses per week; one ED visit in past year. Baseline: nonadherent to controller therapy, poor inhaler technique.

Application of stepwise approach:

  • Assessment: uncontrolled by symptoms and recent exacerbation risk — candidate to step up from intermittent to low-dose ICS (NHLBI, 2020).
  • Intervention: prescribe low-dose ICS with spacer and mask as needed, provide inhaler technique training, asthma action plan, and follow-up in 4–6 weeks to assess control and adherence (CDC, 2023).
  • If symptoms persist at follow-up: escalate to combination ICS/LABA or add LTRA depending on phenotype; consider allergen testing and referral (BTS/SIGN, 2019).
  • Document outcomes and plan for step-down after 3 months of sustained control (GINA, 2024).

Slide 6 — How stepwise management helps clinicians and patients

Benefits for clinicians:

  • Offers a clear, evidence-based algorithm to guide therapy intensity and referral decisions, reducing practice variability (NICE, 2017).
  • Encourages regular reassessment, prompting optimization of adherence, technique, and comorbidity management.

Benefits for patients:

  • Improves symptom control and reduces exacerbation risk by aligning treatment intensity with need; reduces unnecessary exposure to high-dose medications when stepped down appropriately (GINA, 2024).
  • Provides an actionable asthma action plan that empowers self-management and timely healthcare seeking.

Implementation tips for the staff presentation

  • Use one slide per major theme with clear visuals: medication classes, algorithm flowchart, and the patient case.
  • Include practical tools: quick inhaler technique demo checklist, sample asthma action plan, and referral criteria.
  • End with a short quiz or case discussion to reinforce learning and document competency for staff training records.

Conclusion

The stepwise approach provides a pragmatic, evidence-based framework to tailor asthma therapy for adults and children. Emphasizing maintenance controllers, safe rescue strategies, patient education, and planned reassessment fosters sustained control and reduces exacerbations. A concise 5–6 slide staff session focused on classes of drugs, the stepwise algorithm, a concrete patient example, and practical implementation tools will enhance clinic care and patient outcomes (GINA, 2024; NHLBI, 2020).

References

  1. Global Initiative for Asthma (GINA). (2024). Global Strategy for Asthma Management and Prevention. https://ginasthma.org
  2. National Heart, Lung, and Blood Institute (NHLBI). (2020). Guidelines for the Diagnosis and Management of Asthma. https://www.nhlbi.nih.gov
  3. Centers for Disease Control and Prevention (CDC). (2023). Asthma. https://www.cdc.gov/asthma
  4. British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). (2019). British Guideline on the Management of Asthma. https://www.brit-thoracic.org.uk
  5. National Institute for Health and Care Excellence (NICE). (2017). Asthma: diagnosis, monitoring and chronic asthma management (NG80). https://www.nice.org.uk/guidance/ng80
  6. American Academy of Allergy, Asthma & Immunology (AAAAI). (2021). Asthma Guidelines and Resources. https://www.aaaai.org
  7. U.S. Food and Drug Administration (FDA). (2020). Albuterol (Salbutamol) Prescribing Information. https://www.accessdata.fda.gov
  8. Barnes, P. J. (2011). Inhaled corticosteroids in asthma: effects and pharmacology. Respiratory Medicine, 105(9), 1252–1260. https://doi.org/10.1016/j.rmed.2011.05.007
  9. Reddel, H. K., et al. (2019). The new paradigm for asthma management: use of ICS-formoterol as needed. European Respiratory Journal, 53(6). https://doi.org/10.1183/13993003.01243-2019
  10. Bousquet, J., et al. (2012). Global patterns of asthma management and prescribing. The Lancet Respiratory Medicine, 1(1), 34–44. https://doi.org/10.1016/S2213-2600(12)70045-2

Related Assignments